ECB Forum on Central Banking 2023, Lippi (Luiss University) focused on “Inflation and misallocation in New Keynesian models”

Francesco Lippi – Professor Luiss university 2 Governors of central banks, leading academics, economics and finance experts, journalists from across Europe gathered in Sintra, Portugal, to participate in the eighth edition of the European Central Bank’s (ECB) annual forum. The event, titled “Macroeconomic stabilisation in a volatile inflation environment” prominently featured statements by ECB President […]

Read More »

Acronis’ Mid-Year Cyberthreats Report Reveals 464% Increase in Email Attacks

New report unveils troubling trends: cybercriminals exploit AI, persistence in ransomware attacks, and significant surge of data stealers Acronis Mid-Year Cyber Threat Report 2023 SCHAFFHAUSEN, Switzerland, June 29, 2023 (GLOBE NEWSWIRE) — Acronis, a global leader in cyber protection, today released the findings of its Mid-Year Cyberthreats Report, From Innovation to Risk: Managing the Implications […]

Read More »

Timeless travel with VistaJet and Valextra — two icons, one destination

VistaJet x Valextra An exclusively designed five-piece custom luggage collection created for VistaJet Members who fly on the Global 7500 fleet; Limited-edition travel companions thoughtfully crafted for global travel that seamlessly bridge business and leisure; Internationally renowned design, boasting over eight decades of Italian craftsmanship. London, 29 June, 2023: VistaJet, the first and only global […]

Read More »

Depósito Central de Valores to Digitize Securities, Leveraging Nasdaq Technology

Depósito Central de Valores, Chile’s Central Securities Depository, Expands Capabilities to Support the Registration, Transfer and Settlement of Digitized Securities NEW YORK and SANTIAGO, Chile, June 29, 2023 (GLOBE NEWSWIRE) — Nasdaq (Nasdaq: NDAQ) and Depósito Central de Valores (DCV) today announced an extension of their technology partnership, which will allow DCV to issue and […]

Read More »

Junshi Biosciences Announces Initiation of Phase 3 Study of Tifcemalimab plus Toripalimab for Treatment of Limited-stage Small Cell Lung Cancer

SHANGHAI, China, June 29, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the U.S. Food and Drug Administration (“FDA”) has recently agreed a randomized, double-blind, placebo-controlled, multi-regional phase 3 clinical study […]

Read More »